Drug intelligence / Profile preview

PRO-156

Development stage: Unknown
Lead developer: Laboratorios Sophia
Modality: Peptides
Administration: Ophthalmic (topical To Eye)

Overview

PRO-156 is a synthetic peptide therapeutic agent under investigation primarily for ophthalmic use. It has been studied as an ophthalmic solution in a Phase 1 clinical trial to assess its safety and tolerability when administered over the ocular surface of healthy volunteers. The drug is being researched for potential applications in treating various medical conditions, including autoimmune disorders, but its primary documented development is for ophthalmological indications. The mechanism of action and specific molecular targets have not been publicly disclosed[1][2].

Beyond the preview

Go deeper on PRO-156.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO-156.

Explore the full profile